Arbutus Biopharma Terminates Material Definitive Agreement

Ticker: ABUS · Form: 8-K · Filed: 2025-06-25T00:00:00.000Z

Sentiment: neutral

Topics: agreement-termination, corporate-action

TL;DR

Arbutus Biopharma just terminated a big deal. Big changes ahead?

AI Summary

Arbutus Biopharma Corp. announced on June 20, 2025, the termination of a material definitive agreement. The company, formerly known as Tekmira Pharmaceuticals Corp, is based in Warminster, Pennsylvania.

Why It Matters

The termination of a material definitive agreement can significantly impact a company's strategic direction and financial obligations.

Risk Assessment

Risk Level: medium — Termination of a material definitive agreement can introduce uncertainty regarding future operations and financial performance.

Key Players & Entities

Arbutus Biopharma Corp. (company) — Registrant
Tekmira Pharmaceuticals Corp (company) — Former company name
June 20, 2025 (date) — Date of earliest event reported
Warminster, Pennsylvania (location) — Principal Executive Office Address

FAQ

What was the specific material definitive agreement that was terminated?

The filing states that a material definitive agreement was terminated, but does not specify which agreement.

What is the effective date of the termination?

The earliest event reported is June 20, 2025, which is the date of the termination.

What are the implications of this termination for Arbutus Biopharma's ongoing operations?

The filing does not provide details on the implications for ongoing operations.

Were there any financial penalties or obligations associated with the termination?

The filing does not disclose any financial penalties or obligations related to the termination.

Does this termination affect any existing partnerships or collaborations?

The filing does not specify if this termination impacts any existing partnerships or collaborations.

From the Filing

0001171843-25-004094.txt : 20250625 0001171843-25-004094.hdr.sgml : 20250625 20250625073128 ACCESSION NUMBER: 0001171843-25-004094 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20250620 ITEM INFORMATION: Termination of a Material Definitive Agreement ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250625 DATE AS OF CHANGE: 20250625 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Arbutus Biopharma Corp CENTRAL INDEX KEY: 0001447028 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 980597776 STATE OF INCORPORATION: A1 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-34949 FILM NUMBER: 251070970 BUSINESS ADDRESS: STREET 1: 701 VETERANS CIRCLE CITY: WARMINSTER STATE: PA ZIP: 18974 BUSINESS PHONE: 604-419-3200 MAIL ADDRESS: STREET 1: 701 VETERANS CIRCLE CITY: WARMINSTER STATE: PA ZIP: 18974 FORMER COMPANY: FORMER CONFORMED NAME: TEKMIRA PHARMACEUTICALS Corp DATE OF NAME CHANGE: 20110607 FORMER COMPANY: FORMER CONFORMED NAME: TEKMIRA PHARMACEUTICALS CORP DATE OF NAME CHANGE: 20081003 8-K 1 f8k_062525.htm FORM 8-K Form 8-K False 0001447028 0001447028 2025-06-20 2025-06-20 iso4217:USD xbrli:shares iso4217:USD xbrli:shares   UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________ FORM 8-K _________________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):  June 20, 2025 _______________________________ Arbutus Biopharma Corporation (Exact name of registrant as specified in its charter) _______________________________ British Columbia, Canada 001-34949 98-0597776 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 701 Veterans Circle Warminster , Pennsylvania 18974 (Address of Principal Executive Offices) (Zip Code) ( 267 ) 469-0914 (Registrant's telephone number, including area code)   (Former name or former address, if changed since last report) _______________________________ Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Shares, without par value ABUS The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐     Item 1.02. Termination of a Material Definitive Agreement. In December 2021, Arbutus Biopharma Corporation (“Arbutus”) entered into a technology transfer and license agreement (the “License Agreement”) with Qilu Pharmaceutical Co., Ltd. (“Qilu”), pursuant to which Arbutus granted Qilu an exclusive (except as to certain retained rights), sublicensable, royalty-bearing license, under certain intellectual property owned by Arbutus, to